| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Neurocrine Biosciences Inc. | TAK-041 / NBI-1065846 | Anhedonia in depression | Phase 2 | Data Released | Oral | Psychiatric |
| Neurocrine Biosciences Inc. | TAK-653 / NBI-1065845 | Major Depressive Disorder (MDD) | Phase 2 | Data Released | Oral | Psychiatric |
| Neurocrine Biosciences Inc. | TAK-831 / Luvadaxistat (NBI-1065844) | Negative symptoms of schizophrenia | Phase 2 | Trial Discontinued | Oral | Psychiatric |
| Neurocrine Biosciences Inc. | ACT-709478 (NBI-827104) - (STEAMBOAT) | Pediatric epilepsy | Phase 2 | Data Released | Oral | Neurology |
| Neurocrine Biosciences Inc. | NBI-921352 | SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) | Phase 2 | Trial Discontinued | Oral | Neurology |
| Neurocrine Biosciences Inc. | INGREZZA | Tourette syndrome - adults | Phase 2 | Withdrawn | oral | Neurology |
| NeuroSense Therapeutics Ltd. | PrimeC - (PARADIGM) | Amyotrophic Lateral Sclerosis (ALS) | Phase 2b | Data Released | Oral | Neurology |
| NeuroSense Therapeutics Ltd. | PrimeC - (RoAD) | Alzheimer's disease (AD) | Phase 2 | Ongoing | Oral | Neurology |